AU2019346456A1 - Methods and compositions for treating aging-associated impairments using CCR3-inhibitors - Google Patents

Methods and compositions for treating aging-associated impairments using CCR3-inhibitors Download PDF

Info

Publication number
AU2019346456A1
AU2019346456A1 AU2019346456A AU2019346456A AU2019346456A1 AU 2019346456 A1 AU2019346456 A1 AU 2019346456A1 AU 2019346456 A AU2019346456 A AU 2019346456A AU 2019346456 A AU2019346456 A AU 2019346456A AU 2019346456 A1 AU2019346456 A1 AU 2019346456A1
Authority
AU
Australia
Prior art keywords
alkyl
optionally substituted
group
residues selected
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019346456A
Other languages
English (en)
Inventor
Steven P. Braithwaite
S. Sakura Minami
Karoly Nikolich
Sanket V. Rege
Arnaud E.J. TEICHERT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkahest Inc
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkahest Inc filed Critical Alkahest Inc
Publication of AU2019346456A1 publication Critical patent/AU2019346456A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019346456A 2018-09-26 2019-09-25 Methods and compositions for treating aging-associated impairments using CCR3-inhibitors Abandoned AU2019346456A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862737017P 2018-09-26 2018-09-26
US62/737,017 2018-09-26
PCT/US2019/052995 WO2020069008A1 (fr) 2018-09-26 2019-09-25 Procédés et compositions pour traiter des troubles liés au vieillissement au moyen d'inhibiteurs de ccr3

Publications (1)

Publication Number Publication Date
AU2019346456A1 true AU2019346456A1 (en) 2021-04-15

Family

ID=69953286

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019346456A Abandoned AU2019346456A1 (en) 2018-09-26 2019-09-25 Methods and compositions for treating aging-associated impairments using CCR3-inhibitors

Country Status (16)

Country Link
EP (1) EP3856195A4 (fr)
JP (1) JP2022502441A (fr)
KR (1) KR20210065950A (fr)
CN (1) CN112789044A (fr)
AU (1) AU2019346456A1 (fr)
BR (1) BR112021004938A2 (fr)
CA (1) CA3111433A1 (fr)
CL (1) CL2021000724A1 (fr)
CO (1) CO2021003713A2 (fr)
EA (1) EA202190463A1 (fr)
IL (1) IL281578A (fr)
MA (1) MA53743A (fr)
MX (1) MX2021002967A (fr)
SG (1) SG11202102105VA (fr)
TW (1) TW202027752A (fr)
WO (1) WO2020069008A1 (fr)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200538098A (en) * 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
EP1996551A2 (fr) * 2006-03-07 2008-12-03 AstraZeneca AB Derives de piperidine, leur procede de preparation, leur utilisation comme agents therapeutiques et compositions pharmaceutiques les contenant
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
DK2749554T3 (en) * 2009-04-22 2018-04-03 Sma Therapeutics Inc 2,5-disubstituted arylsulfonamide CCR3 antagonists
US20160208011A1 (en) * 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
KR102658724B1 (ko) * 2017-04-05 2024-04-18 알카헤스트 인코포레이티드 Ccr3-저해제를 사용하여 망막-관련 질병을 치료하는 방법 및 조성물
CA3058967A1 (fr) * 2017-04-05 2018-10-11 Alkahest, Inc. Methodes et compositions destinees a traiter des troubles associes au vieillissement a l'aide d'inhibiteurs de ccr3

Also Published As

Publication number Publication date
EP3856195A4 (fr) 2022-06-22
MA53743A (fr) 2022-01-05
CO2021003713A2 (es) 2021-04-08
IL281578A (en) 2021-05-31
TW202027752A (zh) 2020-08-01
CA3111433A1 (fr) 2020-04-02
EP3856195A1 (fr) 2021-08-04
JP2022502441A (ja) 2022-01-11
WO2020069008A1 (fr) 2020-04-02
MX2021002967A (es) 2021-08-11
CN112789044A (zh) 2021-05-11
CL2021000724A1 (es) 2021-10-15
BR112021004938A2 (pt) 2021-06-01
SG11202102105VA (en) 2021-04-29
EA202190463A1 (ru) 2021-06-29
KR20210065950A (ko) 2021-06-04

Similar Documents

Publication Publication Date Title
AU2018250214B2 (en) Methods and compositions for treating aging-associated impairments using CCR3-inhibitors
US10799552B2 (en) Methods for treating diabetic neurotherapy
KR20180064373A (ko) 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체
JP2021193124A (ja) Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
KR20180022792A (ko) 렘 수면 행동 장애의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴 우레아 유도체
JP2011513196A (ja) ドーパミン作動系が破壊された障害もしくは状態の症状を軽減するためまたはその障害もしくは状態を処置するためのｋｃｎｑカリウムチャネル開口薬の使用
US20040208923A1 (en) Acute pharmacologic augmentation of psyschotherapy with enhancers of learning or conditioning
JP6983945B2 (ja) 自己免疫性疾患の処置
ES2950453T3 (es) Compuestos y composiciones farmacéuticas para su uso en el tratamiento de enfermedades asociadas a la retina utilizando inhibidores de la CCR3
US20200054622A1 (en) Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors
CN113811296A (zh) 用src激酶抑制剂治疗纤维化疾病或病症或间质性肺病的方法
JP2017533967A (ja) システアミン組成物を用いるハンチントン病の処置方法
US20100247688A1 (en) Pirenzepine and derivatives thereof as anti-amyloid agents
Hegde et al. To market, to market—2009
AU2019346456A1 (en) Methods and compositions for treating aging-associated impairments using CCR3-inhibitors
EA041892B1 (ru) Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов
CN113924087A (zh) 血清素4受体激动剂对抗应激的预防功效
KR102407982B1 (ko) 기능성 어지럼증을 치료하기 위한 부스피론의 용도
WO2022173334A2 (fr) Procédés, compositions et composés pour le traitement de maladies et d'états liés à l'âge
EA041007B1 (ru) Применение буспирона для лечения функционального головокружения
JP2017132742A (ja) Ａβオリゴマー特異的抗体の新規薬理用途
US20100227844A1 (en) Cannabinoid-1 receptor modulators useful for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period